Adverse effects/events: at least 1 adverse effect ‐ as defined by individual studies. · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Risk of adverse events and serious adverse eventsb, bradycardia, PONV, and signs of residual neuromuscular blockade · Adult patients, ASA I‐IV, who received non‐depolarizing NMBAs
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Risk of adverse events and serious adverse eventsb, bradycardia, PONV, and signs of residual neuromuscular blockade · Adult patients, ASA I‐IV, who received non‐depolarizing NMBAs
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse events · individuals with HL
It is very uncertain whether the intervention changes adverse events (very low certainty).
1 finding from 1 review
Severe adverse events · patients with initial treatment of HIV infection in antiretroviral‐naive individuals
d4T showed no clear difference in severe adverse events compared with AZT (low certainty).
1 finding from 1 review
Serious adverse events · High‐risk HIV‐uninfected individuals (including serodiscordant couples, men who have sex with men and sex workers)
TDF+ FTC showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · High‐risk individuals (including serodiscordant couples, men who have sex with men and sex workers)
TDF showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
All severe adverse events · antiretroviral‐naïve individuals
It is very uncertain whether the intervention changes all severe adverse events (very low certainty).
1 finding from 1 review
Intervention not reported
Severe adverse events: rash · antiretroviral‐naïve individuals
The intervention showed no clear difference in severe adverse events: rash (moderate certainty).
1 finding from 1 review
Adverse events · individuals with sickle cell disease and a leg ulcer
1 finding from 1 review
Adverse events · individuals with sickle cell disease and a leg ulcer
It is very uncertain whether RGD peptide matrix changes adverse events compared with placebo (very low certainty).
1 finding from 1 review
Adverse events · individuals with sickle cell disease and a leg ulcer
1 finding from 1 review
Adverse events · individuals with sickle cell disease and a leg ulcer
1 finding from 1 review
Intervention not reported
Adverse events · individuals without known diabetes mellitus but at high risk for the condition
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events · healthy asymptomatic H. pylori‐infected individuals
1 finding from 1 review
Intervention not reported
Adverse events · individuals with osteoporotic vertebral fracture
1 finding from 1 review
Adverse events · individuals at risk of pressure ulcer development
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · individuals at risk of pressure ulcer development
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · mainly physically active individuals1 partaking in exercise2 designed to produce delayed onset muscle soreness
1 finding from 1 review
Adverse events · Individuals of any age with no reported disability that might affect toothbrushing (including people wearing orthodontic appliances)
1 finding from 1 review